Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01921270 · ClinicalTrials.gov registry record · Phase 1
Dysport for the Treatment of OMD
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01921270 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 18 participants.
The verdict
NCT01921270, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to study the efficacy and safety of AbobotulinumtoxinA (Dysport) for use in Oromandibular Dystonia (OMD).
Interventions
- DRUG Low Dose - AbobotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-02-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01921270
The ClinicalTrials.gov registry entry for NCT01921270 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Low Dose - AbobotulinumtoxinA is the first listed.
NCT01921270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01921270 about?
NCT01921270 is a clinical study titled "Dysport for the Treatment of OMD". The purpose of this study is to study the efficacy and safety of AbobotulinumtoxinA (Dysport) for use in Oromandibular Dystonia (OMD).
What is the current status of trial NCT01921270?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-08. Estimated completion is 2017-02-08.
What interventions are being tested in trial NCT01921270?
The interventions under investigation include: Low Dose - AbobotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT01921270?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.